Pulmonary arterial hypertension associated with interferon therapy: A population-based study

Ravikanth Papani, Alexander Duarte, Yu Li Lin, Yong Fang Kuo, Gulshan Sharma

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been reported, but no population-based estimates of the incidence of the disease after interferon exposure are available. The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large commercial insurance database. Methods: Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes, we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription for PAH-specific medications was used as a surrogate endpoint. Results: We identified 20,113 subjects who received interferon therapy during the study period. The median follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were prescribed to 7 of these subjects. Conclusion: Although our analysis showed that the development of PAH is a rare event with interferon therapy, the risk of developing the disease is several fold higher than that for the general population.

Original languageEnglish (US)
Article number1
JournalMultidisciplinary Respiratory Medicine
Volume12
Issue number1
DOIs
StatePublished - Jan 17 2017

Fingerprint

Pulmonary Hypertension
Interferons
Population
Therapeutics
Healthcare Common Procedure Coding System
Databases
Incidence
International Classification of Diseases
Insurance
Prescriptions
Biomarkers
Pharmaceutical Preparations

Keywords

  • Drug toxicity
  • Interferons
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{1ed80c91ee4243dc878a0c7a62bd004b,
title = "Pulmonary arterial hypertension associated with interferon therapy: A population-based study",
abstract = "Background: Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been reported, but no population-based estimates of the incidence of the disease after interferon exposure are available. The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large commercial insurance database. Methods: Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes, we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription for PAH-specific medications was used as a surrogate endpoint. Results: We identified 20,113 subjects who received interferon therapy during the study period. The median follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were prescribed to 7 of these subjects. Conclusion: Although our analysis showed that the development of PAH is a rare event with interferon therapy, the risk of developing the disease is several fold higher than that for the general population.",
keywords = "Drug toxicity, Interferons, Pulmonary arterial hypertension",
author = "Ravikanth Papani and Alexander Duarte and Lin, {Yu Li} and Kuo, {Yong Fang} and Gulshan Sharma",
year = "2017",
month = "1",
day = "17",
doi = "10.1186/s40248-016-0082-z",
language = "English (US)",
volume = "12",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "Novamedia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Pulmonary arterial hypertension associated with interferon therapy

T2 - A population-based study

AU - Papani, Ravikanth

AU - Duarte, Alexander

AU - Lin, Yu Li

AU - Kuo, Yong Fang

AU - Sharma, Gulshan

PY - 2017/1/17

Y1 - 2017/1/17

N2 - Background: Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been reported, but no population-based estimates of the incidence of the disease after interferon exposure are available. The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large commercial insurance database. Methods: Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes, we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription for PAH-specific medications was used as a surrogate endpoint. Results: We identified 20,113 subjects who received interferon therapy during the study period. The median follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were prescribed to 7 of these subjects. Conclusion: Although our analysis showed that the development of PAH is a rare event with interferon therapy, the risk of developing the disease is several fold higher than that for the general population.

AB - Background: Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been reported, but no population-based estimates of the incidence of the disease after interferon exposure are available. The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large commercial insurance database. Methods: Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes, we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription for PAH-specific medications was used as a surrogate endpoint. Results: We identified 20,113 subjects who received interferon therapy during the study period. The median follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were prescribed to 7 of these subjects. Conclusion: Although our analysis showed that the development of PAH is a rare event with interferon therapy, the risk of developing the disease is several fold higher than that for the general population.

KW - Drug toxicity

KW - Interferons

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=85009865175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009865175&partnerID=8YFLogxK

U2 - 10.1186/s40248-016-0082-z

DO - 10.1186/s40248-016-0082-z

M3 - Article

AN - SCOPUS:85009865175

VL - 12

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - 1

M1 - 1

ER -